Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | USP1 | O94782 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 3/20 | 0.42 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15060890 | 0.87 | CA12 (0.62) | MIFCA12CA1CA2CA9 | |
| SCHEMBL15923722 | 0.86 | CA12 (0.61) | MIFCA12CA1CA2CA9 | |
| SCHEMBL13527240 | 0.86 | CA12 (0.61) | MIFCA12CA1CA2CA9 | |
| SCHEMBL13527035 | 0.84 | MIF (0.58) | MIFCA12CA1CA2CA9 | |
| SCHEMBL16213084 | 0.84 | MIF (0.67) | MIFCA12CA1CA2CA9 | |
| SCHEMBL16220782 | 0.84 | MIF (0.63) | MIFCA12CA1CA2CA9 | |
| SCHEMBL21157711 | 0.80 | FLT3 (0.60) | MIFCA12CA1CA2CA9 | |
| SCHEMBL16212825 | 0.79 | MIF (0.57) | MIFCA12CA1CA2CA9 | |
| SCHEMBL21156448 | 0.78 | CYP2A6 (0.53) | CYP19A1FLT3 | |
| SCHEMBL13722780 | 0.76 | NAMPT (0.65) | KDREPHB4TEKNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211046-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | MIF 196/4885CA12 4447/4885CA1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.